On August 17th, Autobio released a semi-annual performance report stating that the operating income in the first half of 2021 was 1.678 billion yuan, an increase of 39.13% year-on-year; the net profit attributable to shareholders of listed companies was 413 million yuan, an increase of 50.63% year-on-year. Earnings per share were 0.7 yuan, a year-on-year increase of 42.86%, and the net cash flow from operating activities was 522 million, a significant increase, nearly twice the year-on-year increase.

In July, Autobio received the Medical Device Registration Certificate issued by the National Medical Products Administration, product name is coronavirus 2019-nCoV nucleic acid detection kit (PCR-fluorescent probe method). The above achievements have benefited from the company's continuous investment in innovation. During the reporting period, the company’s R&D investment was RMB 225,752,500, accounting for 13.46% of operating income.

As of June 30, 2021, the company has obtained 660 patents, including 39 international patents; obtained 545 product registration (recording) certificates, and obtained 332 product EU CE certification; the company has undertaken 11 national projects, 15 provincial projects, 23 urban-level projects, 10 scientific and technological achievements appraisal (evaluation), and full participation in the formulation of 88 industry standards.

Autobio adheres to the corporate tenet of "Committed to the popularization and improvement of medical laboratory technology, and serves human health", and efforts to provide medical laboratories with products and services with better performance-price ratio, quality-price ratio. "Become a provider of medical laboratory products and services with brand influence; return employees, investors, and society" is the beautiful vision of Autobio.